PrEP for HIV Prevention in Indian Women: NACO, TDF/FTC, Access

• PrEP is a pill (tenofovir + emtricitabine, TDF/FTC) taken every day by HIV-negative people to prevent HIV — over 99% effective when taken consistently.
• It is given FREE through NACO at participating ART centres for people at higher risk, including serodiscordant couples, sex workers, and transgender and other key communities.
• Women must take PrEP DAILY — the 'on-demand' 2-1-1 schedule used by some men does not protect vaginal tissue and is not an option for women.
• PrEP is safe in pregnancy and breastfeeding, and does not interfere with any contraceptive method.
• PrEP prevents HIV only — not other STIs or pregnancy. Combine it with condoms, regular STI testing, and contraception for full protection.
• Generic PrEP is among the cheapest in the world in India — roughly Rs 1,500-3,000 a month privately, free if you qualify under NACO.

Pre-exposure prophylaxis (PrEP) means taking anti-HIV medicine before any possible exposure, so that if HIV does reach your body it cannot take hold. The drug keeps protective levels in your blood and genital tissue, where it blocks the virus early — before it can establish a lasting infection. PrEP is different from PEP (post-exposure prophylaxis, a 28-day course started after a possible exposure) and from ART, the lifelong treatment people take once they already have HIV.

The standard PrEP pill is a single tablet combining tenofovir disoproxil fumarate (TDF) 300 mg and emtricitabine (FTC) 200 mg — sold as Truvada, Tenof-EM, and many affordable Indian generics from Cipla, Mylan, Hetero, Aurobindo and others. Both drugs block a step the virus needs to copy itself. Taken consistently, this combination prevents more than 99 percent of HIV transmissions through sex, and around 74 percent of transmissions through shared injecting equipment.

There is one detail every woman should know: the medicine reaches fully protective levels in vaginal tissue more slowly than in rectal tissue. Daily dosing for roughly 20 days is needed before PrEP gives full vaginal protection, compared with about 7 days for rectal tissue. This single fact explains why daily dosing — not occasional dosing — is the rule for women, and it shapes much of the advice below.

PrEP is also evolving. A long-acting injectable, cabotegravir (CAB-LA), given every two months, performed even better than the daily pill in trials and is approved by the WHO. It is not yet widely available in India outside research and select programmes, but access is expected to grow. A monthly vaginal dapivirine ring and a newer, gentler tablet form (tenofovir alafenamide, TAF, easier on kidneys and bones) are other options expanding globally. For now, the daily TDF/FTC pill remains the backbone of PrEP in India.

India launched its national PrEP programme in 2021 under NACO (the National AIDS Control Organisation), as part of the National AIDS Control Programme Phase V. PrEP is provided free at participating ART centres, with the network expanding year on year. Eligibility follows WHO guidance and currently focuses on people at higher risk of HIV.

Groups currently eligible for free NACO PrEP include:

Beyond these programme groups, WHO recognises that PrEP is medically appropriate for many more women — for example, women whose partner's HIV status or behaviour is uncertain, women who have had recurrent STIs, women who have needed PEP in the past, and survivors of sexual assault with ongoing risk. These situations are not yet all formally enrolled under NACO, but they are valid reasons to consider PrEP through a private prescription.

How to access free NACO PrEP: the easiest routes are through recognised community organisations that partner with NACO (such as the Humsafar Trust in Mumbai, the Naz Foundation in Delhi, Sahodaran in Chennai, and many regional groups), directly through your nearest ART centre, or via your State AIDS Control Society (SACS), which can tell you where PrEP is offered locally. These services also provide the counselling and three-monthly monitoring that go with PrEP.

If you don't currently fit NACO eligibility but want PrEP, the private route is simple: any qualified doctor — a GP, a gynaecologist, a sexual-health or HIV specialist — can prescribe TDF/FTC. The tablets are sold widely in Indian pharmacies for roughly Rs 1,500-3,000 a month for generics, among the lowest prices anywhere in the world. You will still need the same baseline tests and three-monthly check-ups, done at any private lab.

Before you start PrEP, a short set of tests confirms you are HIV-negative, checks that PrEP is safe for you, and picks up any STIs that should be treated at the same time. These tests are free for eligible groups at ART centres and NACO ICTC counselling centres, or available at any private lab.

The essential tests are:

Why each matters: confirming HIV-negative status first is critical, because starting PrEP in someone who unknowingly already has HIV can make the virus resistant to these drugs and complicate later treatment. The hepatitis B check matters because tenofovir also treats hepatitis B — starting and then suddenly stopping it in someone with active hepatitis B can trigger a dangerous flare. And the kidney check sets a baseline, since tenofovir carries a small risk of affecting kidney function; PrEP is generally safe to start with an eGFR above 60.

Alongside these, you'll usually have STI screening — a combined chlamydia and gonorrhoea test, a syphilis test (VDRL/RPR), and sometimes hepatitis C and herpes serology. Untreated bacterial STIs such as Chlamydia in Indian Women: Symptoms, Testing and Treatment, Gonorrhea in Women: Symptoms, Testing and Treatment in India and Syphilis in Women: Stages, Tests and Penicillin Cure both cause their own problems and can increase HIV risk, so treating them strengthens your overall protection. A pregnancy test and a quick medication review round out the visit.

At the first visit your provider takes a history, draws blood (results in 1-3 days), counsels you on adherence and side effects, and either dispenses your first month straight away or starts you once results confirm you are HIV-negative. Approaches vary slightly between NACO programmes and private clinics, but the principle is the same: start only once HIV-negative status is confirmed.

PrEP comes with simple, regular check-ups. These catch the rare breakthrough infection early, treat any new STIs, keep an eye on your kidneys, and give you a moment to talk through how the pills are fitting into your life. The WHO and CDC schedule is built around a visit every three months.

Every three months: an HIV test (so that any rare breakthrough is found and managed quickly), a pregnancy test if relevant, and a short check-in on how you are taking the pills and whether your risk has changed.

Every six months: STI testing (chlamydia and gonorrhoea, syphilis, and others if symptoms suggest), plus a repeat kidney function test (creatinine and eGFR).

Once a year: a fuller review — an extended STI panel, repeat hepatitis B and C screening, and a broader conversation about whether PrEP still suits you or whether another approach might fit better.

Cost of monitoring: free at NACO ART centres for eligible groups. Privately, each three-monthly visit runs about Rs 1,000-3,000 (consultation plus tests), so roughly Rs 5,000-15,000 a year.

If you ever test HIV-positive while on PrEP, the response is straightforward: stop PrEP and switch immediately to a full treatment regimen — usually TLD (tenofovir-lamivudine-dolutegravir), which builds on the same tenofovir you were already taking. This is rare (PrEP is over 99 percent effective when taken consistently) and almost always linked to missed doses. With a prompt switch, long-term outcomes are excellent and HIV becomes a manageable, long-term condition.

Adherence is where PrEP succeeds or fails, so your visits include practical support — pill boxes, phone reminders, tying the dose to a daily habit like brushing your teeth or your morning chai, and peer support. Missing the odd dose is recoverable: simply take your next dose and carry on daily, no catch-up doses needed. It is persistent irregular dosing that weakens protection.

PrEP works the same way in everyone, but a few things matter specifically for women — because of how the medicine behaves in vaginal tissue and how it fits with pregnancy, breastfeeding and contraception.

Daily dosing is required — there is no on-demand option for women. Some men who have sex with men use a 2-1-1 'on-demand' schedule (two tablets before sex, then one tablet on each of the next two days) because the drug protects rectal tissue quickly. Vaginal tissue takes longer — about 20 days of daily dosing — to reach fully protective levels. On-demand dosing simply does not protect vaginal exposure, so women must take PrEP every day for the whole time they are at risk. This is biology, not bureaucracy.

Pregnancy: PrEP with TDF/FTC is considered safe in pregnancy and is recommended for women at ongoing HIV risk. The same drugs are used routinely in pregnant women living with HIV, with extensive reassuring safety data. Continuing PrEP through pregnancy protects you and indirectly protects the baby by preventing the HIV you might otherwise pass on. If you are living with HIV and planning a family, our guide to HIV and pregnancy in India covers safe conception and PMTCT.

Breastfeeding: PrEP is also considered safe while breastfeeding. Only tiny amounts of the drugs pass into breast milk — far below treatment doses — with no harmful effects seen in babies. The WHO and CDC support continuing PrEP through breastfeeding for women at risk.

Contraception: PrEP does not interact with any hormonal method — the combined pill, the mini-pill, the hormonal or copper IUD, the injection, the implant or the vaginal ring all work normally alongside it, and PrEP keeps working too. If you also need contraception, you can choose freely; our overview of contraception while breastfeeding may help with specific situations.

Your cycle: there is no need to change PrEP around your period — keep taking it daily through every phase.

Vaginal health: early research suggests the vaginal microbiome (especially protective Lactobacillus bacteria) may influence how tenofovir works locally. The everyday takeaway is simple — keep taking PrEP daily, avoid douching, and treat recurrent infections such as recurrent bacterial vaginosis when they occur.

TDF/FTC has been used by millions of people for more than a decade with a strong safety record. Most side effects are mild and settle quickly; serious problems are rare and picked up by routine monitoring.

In the first few weeks, some people (about 1 in 5) notice a mild 'start-up' phase — a little nausea, stomach upset, headache or tiredness. It usually fades within four to six weeks. Taking the pill with food and at the same time each day helps; if it lingers or feels severe, tell your provider.

Less common effects include a mild rash or a small, usually temporary dip in weight. Two longer-term effects are worth knowing about. First, the kidneys: tenofovir carries a small risk of reducing kidney function, mostly in people who already have kidney problems, diabetes, high blood pressure, or who take other kidney-stressing drugs — which is exactly why six-monthly kidney tests are part of the plan. For someone starting with healthy kidneys, the risk is very low.

Second, bone density: tenofovir can cause a small (1-2 percent) drop in bone density in the first year, which then stabilises. For most healthy adults this has little practical effect, but the newer TAF formulation is gentler on bones where available. If bone health is already a concern for you, our guides on bone density (DEXA) scans and osteoporosis prevention in Indian women explain how it is measured and protected.

Over a decade of follow-up shows no increased cancer risk, no harmful metabolic, neurological or reproductive effects, and that the rare kidney changes usually reverse when the drug is stopped. In short, PrEP sits comfortably alongside other widely used preventive medicines — minor side effects in a minority, rare serious effects caught by monitoring, and a large reduction in the outcome that matters: getting HIV.

PrEP is brilliant at one job — preventing HIV. It does not prevent other sexually transmitted infections (chlamydia, gonorrhoea, syphilis, herpes, HPV, hepatitis B and C, trichomoniasis) and it does not prevent pregnancy. The strongest protection comes from layering: PrEP for HIV, condoms for other STIs and pregnancy, and regular screening to catch anything early. Our overview of STIs in Indian women explains what to test for and how often.

Using condoms alongside PrEP adds a second layer against HIV, blocks the STIs PrEP misses, and prevents pregnancy — so condoms-plus-PrEP is the gold standard for anyone who can use them. (For how well condoms actually protect, see our notes on how effective condoms really are.)

But here is where PrEP changes lives for women in India. Many women cannot reliably get a partner to use a condom. PrEP puts HIV prevention entirely in the woman's own hands — it is taken by mouth, leaves no visible trace, and slots into a daily routine without anyone else's permission or knowledge. For a woman whose husband refuses condoms, this independence is the whole point. A female condom, which a woman also controls, can add protection against other STIs.

Because PrEP users tend to have higher background STI rates, the three- and six-monthly screening built into PrEP care is deliberate — it finds and treats bacterial STIs early, both for your own health and because untreated STIs can nudge HIV risk back up. An emerging strategy called doxy-PEP (a dose of doxycycline after sex to cut bacterial STIs) shows promise in some groups but is not yet routine for women in India; ask your provider if you're curious.

And to be clear on pregnancy: PrEP does nothing to prevent it. If you don't want to conceive, you'll need contraception too — every method is compatible with PrEP. If you do want to conceive, you can stay on PrEP throughout; it is safe before and during pregnancy.

One of the most important ideas in HIV care is U=U — undetectable equals untransmittable. When a person living with HIV is on effective treatment and their viral load stays undetectable, they do not pass HIV to sexual partners. This has transformed the conversation for serodiscordant couples (one partner HIV-positive, one HIV-negative).

If the HIV-positive partner has had a sustained undetectable viral load for at least six months, the risk of passing HIV during sex is essentially zero. Large studies (HPTN 052, PARTNER, PARTNER 2, Opposites Attract) found no HIV transmissions in this situation. In other words, U=U alone can be full protection — the negative partner does not strictly need PrEP.

Some couples still choose to use both — U=U for the positive partner and PrEP for the negative partner — usually for extra peace of mind, or during the early months when viral suppression is still being established, or if the positive partner's treatment adherence has been inconsistent, or while planning a pregnancy. The added medical protection beyond U=U alone is small, but the reassurance can matter.

For U=U alone to be relied on, a few conditions should be met: the positive partner is on effective treatment with a documented undetectable viral load (under 200, ideally under 50, copies/mL) for at least six months, takes treatment consistently, has no untreated STIs, and keeps up six-monthly viral load checks. With these in place, protection is essentially complete.

There is no single right answer — how much extra safety margin a couple wants beyond U=U is personal, and worth discussing together with the HIV physician. For couples planning a baby, natural conception is possible with U=U at essentially zero risk; some add PrEP for the conception window, others don't.

PrEP's biggest barrier in India is not the medicine — it is awareness. Outside the specific groups NACO targets, very few people know PrEP exists, fewer know who qualifies for it free, and fewer still know how to access it. Many women who could benefit have simply never heard of it.

Stigma is the second barrier. Talking about HIV prevention beyond 'use a condom' is still uncommon, and the harmful assumption that 'good women don't need HIV prevention' keeps many people from asking. Women in higher-risk situations — including those in violent or controlling relationships — carry an extra layer of stigma. Provider attitudes vary too: some doctors prescribe PrEP enthusiastically, others are hesitant or even judgemental. You are entitled to non-judgemental care.

Access is uneven geographically. States with strong, long-standing HIV programmes — Maharashtra, Karnataka, Tamil Nadu, Andhra Pradesh, Manipur, Mizoram, Nagaland and Delhi among them — generally have better PrEP access. Smaller cities and rural areas are catching up, and may rely more on private prescribing for now. Within cities, community organisations working with specific groups are often the most welcoming entry points.

The private route is genuinely affordable here. Generic TDF/FTC costs about Rs 1,500-3,000 a month — a fraction of prices abroad — and three-monthly monitoring adds roughly Rs 1,000-3,000 per visit. Online consultations with HIV specialists can prescribe PrEP and order the tests. Counting medicine and monitoring, a year of private PrEP comes to roughly Rs 25,000-50,000.

Looking ahead, NACO is expected to widen eligibility over time, long-acting injectable PrEP should become more available as supply grows, and integrating PrEP into routine antenatal, family-planning and STI services would reach many more women. For survivors of sexual violence, immediate care and PEP come first — see our guides on survivor care after sexual assault and consent within marriage.

PrEP is taken for as long as you are at risk — not necessarily forever. You might consider stopping if you enter a confirmed mutually HIV-negative monogamous relationship, your circumstances change, your HIV-positive partner reaches sustained undetectable viral load (U=U applies), or you experience side effects that warrant a different approach.

Stopping safely matters. For women using PrEP for vaginal exposure, the guidance is to keep taking it daily for 28 days after the last possible exposure to be fully covered, rather than stopping abruptly. Do a final HIV test at the end of that period, and a confirmatory test three months after the last exposure.

One crucial safety point: hepatitis B. If you have active hepatitis B, suddenly stopping tenofovir can trigger a severe flare. This is exactly why hepatitis B is checked before you start. If you are HBsAg-positive, your stopping plan must include ongoing hepatitis B treatment, ideally guided by a liver or HIV specialist. Never stop TDF/FTC abruptly if you have hepatitis B without that plan in place.

Restarting is easy if your situation changes again — repeat the baseline workup (HIV test, kidney function, STI screen) and resume daily dosing. Remember the roughly 20-day lead time for full vaginal protection, so keep using other prevention during those first weeks.

Whether you use PrEP continuously for years or only during specific higher-risk periods, both patterns are completely appropriate. The choice is yours, reviewed at each visit with your provider.

PrEP is a planned, preventive medicine, so most contact with a clinician is routine. But reach out promptly in these situations:

If a possible HIV exposure happens and you are NOT already established on PrEP (or have missed several days of doses), seek care urgently — within 72 hours PEP (post-exposure prophylaxis) can still prevent HIV, and the sooner it starts the better.

• WHO — Pre-exposure prophylaxis (PrEP)
• NACO (National AIDS Control Organisation), India — Ministry of Health and Family Welfare
• CDC — Pre-Exposure Prophylaxis (PrEP)
• WHO — Undetectable = Untransmittable (U=U) and viral suppression
• U.S. Public Health Service — Preexposure Prophylaxis for the Prevention of HIV Infection: Clinical Practice Guideline